The FDA on June 12, 2024, granted traditional approval to RETEVMO® for adult and pediatric patients 2 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). RETEVMO® is a product of Eli Lilly and Company.
Bottom Ad
Advertisement
Subscribe
